This search includes all content on the Scottish Parliament website, except for Votes and Motions. All Official Reports (what has been said in Parliament) and Questions and Answers are available from 1999. You can refine your search by adding and removing filters.
To ask the Scottish Government, further to the answer to question S4W-20040 by Alex Neil on 17 March 2014, whether it will provide a breakdown by medicine of the £21.7 million Rare Conditions Medicines Fund expenditure.
Questions and Answers
Date answered:
6 August 2014
At this point the pharmaceutical company will also have the option to submit a new or revised Patient Access Scheme (PAS) aimed at improving the cost-effectiveness of the medicine. A company may decide to offer a new or revised PAS and proceed to the Scottish Medicines Consortium (SMC) meeting for a decision without ...
Questions and Answers
Date answered:
10 September 2012
To ask the Scottish Executive what account the Scottish Medicines Consortium takes of the budgetary impact of the uptake of ultra-orphan medicines when assessing their cost effectiveness.
If a medical professional has prescribed a medication for a person and told them that they are fine to drive if they take it appropriately, they are fine to continue to do so. For some medicines, a doctor will say that a person is not safe to drive while taking that medicine.
The MedTech Health Innovation Partnership (HIP), the Medicines Strategic Engagement Group (the equivalent of a medicines HIP) and the Digital Health Innovation Partnership will all report to the Innovation Partnership Board (IPB).